Peripherally, ANXA1 may act in an endocrine manner to regulate inflammatory biomarkers to dampen inflammation, regulate insulin secretion and improve the metabolic profile to reduce the risk of developing obesity associated co-morbidities. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.